-
1 Comment
Qualigen Therapeutics, Inc is currently in a long term downtrend where the price is trading 36.9% below its 200 day moving average.
From a valuation standpoint, the stock is 99.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 12.6.
Finally, its free cash flow fell by 1255.1% to $-5M since the same quarter in the previous year.
Based on the above factors, Qualigen Therapeutics, Inc gets an overall score of 1/5.
Exchange | F |
---|---|
CurrencyCode | EUR |
ISIN | None |
Sector | Healthcare |
Industry | Biotechnology |
PE Ratio | None |
---|---|
Target Price | 7.75 |
Dividend Yield | 0.0% |
Market Cap | 7M |
Beta | 0.06 |
Qualigen Therapeutics, Inc., a biotechnology company, develops novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a rapid diagnostic testing system. The company is developing QN-302 for the treatment of pancreatic ductal adenocarcinoma; QN-247, a DNA coated gold nanoparticle cancer drug candidate that targets various cancers; RAS-F, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and STARS blood cleansing system, a DNA/RNA-based treatment device that removes tumor-produced compounds and viruses from a patient's blood. Qualigen Therapeutics, Inc. was founded in 1996 and is based in Carlsbad, California.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 7R9B.F using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025